Search

The article discusses the steps to early detection of age-related macular degeneration (AMD) and how to evaluate optical coherence tomography (OCT) findings. Topics include fundus findings that increase the risk for exudative conversion, symptoms of dry-to-wet conversion, and techniques that can benefit evaluation of eyes with AMD.

"We demonstrated that intermittent fastingby skipping breakfast was significantlyassociated with a reduced risk of AMD in arepresentative elderly population, especiallyin individuals with age less than 70 years,obesity, and urban residence", Choi andcolleagues wrote. RETINA Intermittent fasting makes a difference in olderindividuals, study results show Skipping breakfast may actually be a goodthing for a select population, according toSouth Korean investigators. [Extracted from the article]

The article provides information on clinical trials of cholesteryl ester transfer protein (CETP) inhibitors such as anacetrapib from Merck & Co., dalcetrapib from Roche, and evacetrapib from Eli Lilly & Co. It cites the news that the torcetrapib of Pfizer had increased the risk of death of patients. Researchers consider blocking CETP is beneficial due to its ability to raise levels of high-density lipoproteins (HDLs). Other researchers are still not convinced on the premise of CETP inhibition.

The article explains the effect of cholesteryl ester transfer protein (CETP) on patients with low high density lipoproteins (HDL) and increased cardiovascular risk.

The article focuses on the role of high-density lipoprotein (HDL) cholesterol as a causative factor in cardiovascular risk and type 2 diabetes. It refers to a panel discussion of healthcare professionals involved in the care of patients with dyslipidaemia, particularly when associated with type 2 diabetes. The panel discussion dealt with various aspects like association between HDL and cardiovascular risk.

Discusses issues and concerns surrounding metabolic syndrome, a set of disorders that significantly increases the risk of heart disease. Complexity of the syndrome's biochemical underpinnings; Major components including excess weight, high blood pressure, dyslipidemia of triglycerides and low levels of high-density lipoproteins in the blood; Lack of full understanding about the causes of the syndrome; Impact of insulin resistance; Diagnosis of the metabolic syndrome; U.S. National Cholesterol Education Program Adult Treatment Panel III parameters; Opportunities for drug development; Lack of regulatory criteria for therapeutic outcomes.

The article focuses on the use of high density lipoprotein (HDL) as targets for type 2 diabetes and cardiovascular disease management.

The article focuses on total LDL or total HDL cholesterol ratio that is the best determinant of cardiovascular risk for use in primary care. Total cholesterol, however, is not by itself the major risk factor for cardiovascular disease. The two cholesterol components commonly measured are LDL cholesterol and HDL cholesterol. The main proportion of cholesterol is transported in the blood as LDL cholesterol. HDL plays a key role in reverse cholesterol transport, whereby some of the cholesterol is removed from the cholesterol-laden plaque and recycled back to the liver, and HDL has other protective effects like inhibiting LDL oxidation, antithrombotic and anti-inflammatory effects.

The article discusses research which showed that adults who consumed fatty fish thrice a week, and a regular consumption of whole grains and bilberries showed increased HDL diameter and polyunsaturation in plasma fatty acids.

The article discusses research published in the journal "Lancet Diabetes & Endocrinology" on the link between high high-density lipoprotein (HDL) function and lower risk to heart disease.

The article presents the findings of a study on the role of supervised home-based resistance training using high-quality equipment in improving strength, high-density lipoprotein cholesterol (HDL-C) and quality of life in patients with type 2 diabetes. According to the study, although supervised, facility-based resistance training improves glycemic control and body composition in type 2 diabetics, home-based resistance training using inexpensive basic equipment has not shown similar benefits.

The author focuses on the health benefits of raising the levels of high-density lipoprotein cholesterol (HDL-C). He mentions that a low serum level of HDL-C increases the risk for coronary artery disease (CAD), stroke and sudden death based on epidemiologic studies. He cites that studies have shown an association between reduced risk for CAD and elevated HDL-C levels. He adds that deriving novel therapeutic approaches to raise HDL-C level will require more investigations.

I work on a secure mental health unit, where there are several patients with long-standing mental illnesses who are obese or have high body mass indices. Many patients have hypertension and poor diets, are heavy smokers and are physically inactive. [ABSTRACT FROM AUTHOR]

The article reports on the impact of gastric banding on high-density lipoprotein (HDL), as revealed in the results of a study that was conducted by researcher Amita Singh and colleagues in the U.S.

This article reports on the decision of drug manufacturer Roche to cancel a Phase III trial of dalcetrapib, a compound that raises levels of high-density lipoprotein.

The article reports that questions remain on the potential use of high density lipoproteins (HDL) in predicting and preventing cardiovascular diseases (CVD).

The article discusses a research study which reported improved high-density lipoprotein (HDL) and triglyceride levels in patients with human immunodeficiency virus (HIV) receiving antiretroviral therapy following lifestyle change and a combination treatment with niacin and fenofibrate.

The article discusses research being done on the structure of human plasma-derived high-density lipoprotein (HDL) which could help explain its cardioprotective effect, referencing a study by R. Huang e al, published in a 2011 issue of "Nature Structural and Molecular Biology."

The article discusses research by biochemists at the University of Cincinnati wherein the first structural information on high-density lipoprotein (HDL) isolated from human plasma was obtained, and its consequences on the future development of drugs and the understanding of HDL structural organization.

The article discusses research study being done on the association of prolonged sedentary time with increased waist circumferences, lower levels of high density lipoprotein (HDL), increased C-reactive protein (CRP) levels, and higher triglycerides, which references a study by G. N. Healy and colleagues in a 2011 issue of the "European Heart Journal."

This section offers news briefs related to cholesterol in the body. A study published in the December 2008 issue of "The FASEB Journal" found that poor high-density lipoprotein (HDL) cholesterol is not good for one's health. A study presented at the American Heart Association 2008 Scientific Sessions found that consuming soy protein can result to a significant reduction in blood cholesterol levels. A study published in the "American Journal of Clinical Nutrition" found that the 20% pistachio diet reduced low-density lipoprotein (LDL) cholesterol.

The article reports on a core-shell complex that mimics high density lipoprotein (HDL) developed by researchers from Northwestern University in Evanston, Illinois. According to the author, the researchers have demonstrated that the functionalized gold nanoparticles bind to a fluorescent labeled cholesterol analog and determined the first quantitative cholesterol-binding constant for a synthetic HDL.

This section discusses various research on issues concerning cholesterol. A study suggested that lower levels of high-density lipoproteins is not linked to increased risk of heart disease. Another study found that statins reduced the levels of prostate-specific antigen (PSA). A research discovered that patients who took lipophilic statins have reduced rate of developing cancer.

The article discusses research on the influence of hyperlipidemia on the survival of patients with amyotrophic lateral sclerosis (ALS). It references a study by Vincent Meininger and colleagues, published in "Neurology." The study included 369 patients diagnosed with ALS and 286 healthy participants whose blood samples were analyzed. Study authors concluded that patients with ALS who have low ratio of low-density lipoprotein (LDL) to high-density lipoprotein have increased risk of mortality.

The article discusses a study on stress handling and cholesterol conduced by researchers at the University of Hawaii. According to the study which involved 716 men, those who remain calm in stressful instances can have higher levels of high-density lipoproteins (HDL), a good cholesterol. The study also found that low-density lipoprotein (LDL) levels are not affected by negative reactions to stress.

The article focuses on the findings of studies on the effect of high-density lipoprotein cholesterol on coronary atherosclerosis (HDL-C) presented during the American College of Cardiology annual meeting in New Orleans, Louisiana. The studies compared groups of patients receiving torcetrapib plus atorvastatin to atorvastatin monotherapy. Professor Daniel Rader cited the implications of blood pressure increase due to torcetrapib. He noted that HDL is inversely associated with cardiovascular risk.

The article discusses the effectiveness of niacin, in its therapeutic form of nicotinic acid, in increasing high-density lipoprotein levels. The Coronary Drug Project showed that niacin was the only treatment out of 5 that were tested that prevented second heart attacks. Investigators found that the addition of niacin to low-density lipoprotein-lowering statins can slow the progress of cardiovascular disease and reduce the risk of heart attack.

The article reports on the findings of the study conducted by Cleveland Clinic researchers regarding the ability of the drug torcetrapib from Pfizer Inc. to slow down plaque buildup in the coronary arteries. It was found that the drug does not slow arterial plaque buildup despite increasing the levels of high-density lipoprotein cholesterol by 60 percent. Pfizer already ceased the development of the drug after the safety board revealed that the drug increased the risk of patient death.

The article reports that Pfizer Inc. has stopped the development of cholesterol agent torcetrapib. It is being developed to elevate the levels of high-density lipoproteins and prevent cardiovascular disease. However, this medicine has caused 82 deaths among its users. As a result, the company's shares decline by 12% enabling Pfizer to initiate cost cutting.

This article discusses the study of the mortality rate of critically ill patients with low blood levels of high-density-lipoprotein (HDL) cholesterol on the first day of severe sepsis. Sepsis is the leading cause of death in critically ill patients, and is fatal for 30 percent to 50 percent of them. Lipoproteins, a family of proteins in human blood that normally bind to lipids, have been found to bind and neutralize toxic germ products, and so might benefit patients with sepsis. The researchers measured serum levels of lipids and lipoproteins of 63 patients in the intensive care unit of a 2,000-bed, tertiary-level university hospital on the first day of severe sepsis and monitored them for 14 days. The investigators found that patients who on the first day of sepsis had an HDL cholesterol level less than 20mg/dL and apolipoprotein A-1 less than 100mg/dL had a higher rate of overall and sepsis-attributable 30-day mortality.

There are many patients without proven arterial disease, and thus in the primary prevention group, who have a high total cholesterol, but a total: high density lipoprotein (HDL) ratio of <5.0. The author says that at the outset these women should use risk tables in the BNF which use the total cholesterol: HDL. HDL cholesterol levels are subject to regulation via lifestyle, environment and medication, and are also altered during illness. HDL cholesterol levels are inversely associated with the development of coronary heart disease (CHD) or stroke, and high levels (>60 mg/dl, approximately 1.5 mmol/1) have been deemed a 'negative' CHD risk factor in the U.S.

Reports on the study that moderate exercise can increase high-density lipoproteins (HDL) cholesterol. Factors which contribute to the levels of HDL.

Reports that fiber, alcohol, and vigorous exercise can increase levels of high-density lipoprotein (HDL) or the `good' cholesterol, thus fight against high cholesterol levels.